The BasicsTwo Viruses, One Body
HIV and hepatitis C (HCV) are both bloodborne viruses — they spread mainly through contact with infected blood. Because they travel the same routes, coinfection is common. In the United States, an estimated 21% of people living with HIV also have hepatitis C (estimates range from about 6% to 30%, depending on the community studied). Among people who inject drugs and are living with HIV, that number rises to 62–80%.[1]
HIV targets the immune system. HCV targets the liver. When both are present, each one makes the other worse. HIV weakens the immune response that would otherwise help hold HCV in check, and HCV-related liver damage moves faster in people living with HIV — even in people whose HIV is fully suppressed on antiretroviral therapy.
Before the arrival of direct-acting antivirals (DAAs), treating hepatitis C in someone living with HIV was long, painful, and often unsuccessful. The old interferon-based therapies caused brutal side effects and cured less than half of coinfected people. That era is over. Modern DAA treatment cures hepatitis C in 95% or more of coinfected people — the same cure rate as in people with HCV alone.
Why coinfection numbers can look confusing. The most-cited estimate — that roughly one in five people living with HIV in the U.S. also has HCV — comes from CDC data collected around 2009.[1] Newer national surveillance from 2014 across 17 jurisdictions found the overall rate closer to 6.7% among people living with diagnosed HIV,[3] though rates remain far higher in specific communities — people who inject drugs, gay and bisexual men with HIV, and populations in states with heavier IDU burden like Florida. Different studies count different populations, so any single percentage is a snapshot, not the whole story.
Why It MattersWhat Coinfection Does to the Body
When HIV and HCV live in the same body, the risks compound. Each virus makes the other harder on the body than it would be alone.
Faster liver damage. Scarring of the liver (called fibrosis) moves significantly faster in people living with HIV than in people with HCV alone. Cirrhosis (advanced scarring) develops sooner, and the risk of end-stage liver disease and liver cancer is higher — even in people whose HIV is fully suppressed.[2]
A leading non-AIDS cause of death. Before DAAs existed, HCV-related liver disease became one of the top causes of death for people living with HIV in countries with good HIV treatment.[3] HIV medication was keeping people alive long enough for hepatitis C to catch up with them. That sentence should never have been possible — and with today's DAAs, it does not have to be true anymore.
Complications beyond the liver. HCV keeps the immune system on alert and can push CD4 cells toward cell death, even when HIV treatment is working. It can also throw off how CD4 counts read: people whose spleen has enlarged because of HCV-related liver disease can have low CD4 counts for that reason alone, not because HIV is uncontrolled. That distinction matters for how care teams interpret lab results.
Hepatitis C isn't only a liver disease. It can also cause blood vessel inflammation (vasculitis), a specific kind of kidney disease, and a skin condition called porphyria cutanea tarda.[4] In coinfection, these additional effects add another layer of health burden — and give one more reason not to leave HCV untreated.
Understanding Your LiverWhat Fibrosis Stage Means — And How It's Measured Without a Biopsy
Providers describe liver scarring on a five-step scale from F0 (no scarring) to F4 (cirrhosis — advanced, established scarring). Knowing where you fall on that scale tells you and your provider two things: whether curing hepatitis C alone is enough, or whether you'll also need long-term liver cancer screening after cure.
You do not need a biopsy to find out. A FibroScan is a painless, ten-minute ultrasound-based scan that measures liver stiffness, which correlates with fibrosis stage. Simple blood-test-based scores called APRI and FIB-4 use standard labs you probably already get and estimate fibrosis without any new test at all. Both approaches are endorsed by hepatology guidelines as first-line ways to stage the liver in someone with hepatitis C.[13]
Ask before you start treatment. Your provider should tell you your fibrosis stage before starting DAAs — from either a FibroScan, an ultrasound plus blood work, or a FIB-4 score. If nobody has mentioned it, ask. This one detail changes what your post-cure care looks like for the rest of your life.
Risk FactorsWho Is Most at Risk for Coinfection?
Because HIV and HCV move through the same routes, the communities most affected overlap. Being in one of these groups doesn't mean you have HCV — it means testing is especially important.
Sexual transmission of HCV: HCV is primarily bloodborne, but sexual transmission is now well documented among gay and bisexual men, especially those living with HIV. Higher-risk factors include condomless receptive anal sex, shared sex toys, non-injection recreational drug use during sex ("chemsex"), and having another sexually transmitted infection at the same time.[5] People taking PrEP should also be included in routine HCV screening.
TestingGet Tested — And Keep Getting Tested
The CDC recommends that every person living with HIV be tested for hepatitis C when they first enter care. That is a baseline expectation, not an optional add-on.[6]
For people with ongoing risk — especially people who inject drugs and gay and bisexual men — annual HCV testing is recommended, and more frequent testing may be appropriate based on exposure. One important detail: after someone has been cured of HCV, follow-up testing should use an HCV RNA test rather than an antibody test, because the antibody typically remains positive for life even after successful treatment.[1]
Reinfection is possible. Being cured of hepatitis C does not create immunity. Someone who has been cured can catch HCV again if they are exposed. This is especially important for people who inject drugs and for gay and bisexual men with ongoing sexual risk. Post-cure monitoring should continue — and, if needed, retreatment works too.
Behind the Blood DrawWhat the HCV Test Actually Is
An HCV test starts with a single tube of blood — usually drawn during your routine HIV labs. That tube runs first for an HCV antibody: has your immune system ever seen the virus? If the antibody is negative, you've never been exposed and the test is done.
If the antibody is positive, the same tube gets a follow-up test called HCV RNA (also called a viral load or PCR test), which asks the different question: is the virus in your body right now? A positive antibody with a negative RNA means you were exposed at some point but cleared the virus — either on your own or through past treatment. A positive antibody with a positive RNA means you have active hepatitis C and are eligible for treatment.[14]
Most labs return results within one to two weeks. Nothing about the test itself is different for people living with HIV — same tube, same lab, same turnaround.
Why the antibody stays positive forever. Once your immune system has seen HCV, it makes antibodies against it — and those antibodies typically stay in your blood for the rest of your life, even after successful cure. That's why post-cure monitoring uses the HCV RNA test, not the antibody. A positive antibody after cure is not a relapse — it's a scar in your immune memory, nothing more.
TreatmentHCV Is Curable — Even with HIV
This is the most important section on this page. Hepatitis C is curable. Not just manageable. Not just treatable. Curable. And the cure rate for people living with HIV who also have HCV is the same as for people with HCV alone — over 95%.[7]
The treatment is a class of pills called direct-acting antivirals (DAAs). Most people take them by mouth for 8 to 12 weeks and experience only mild side effects, if any. The old regimens used weekly injections of interferon and daily ribavirin, caused months of flu-like illness, and cured fewer than half of coinfected people. Multiple clinical trials have now confirmed that people living with HIV are no longer a "hard to treat" group for HCV. That label belongs to the interferon era, not to today.
First-Line DAA Regimens for HIV/HCV Coinfection
Glecaprevir/pibrentasvir (Mavyret) — works against every HCV genotype ("pan-genotypic"), taken for 8 to 12 weeks. Compatible with most modern HIV regimens.
Sofosbuvir/velpatasvir (Epclusa) — also pan-genotypic, taken for 12 weeks. Should not be combined with efavirenz-based HIV medication, because efavirenz significantly lowers velpatasvir levels.[8]
Both cure over 95% of coinfected people — measured as SVR, or sustained virologic response.
What is SVR? Sustained virologic response means HCV is undetectable in your blood 12 weeks after finishing treatment. If you reach SVR, you are cured — the virus is gone. Your liver can start to heal, though scarring (cirrhosis) that was already there may not fully reverse.
Order matters. If someone needs to start both HIV and HCV treatment, current guidelines recommend starting HIV treatment first to let the immune system stabilize, then adding HCV treatment. The two are not usually started on the same day — most people do better adjusting to one regimen at a time.
Do not interrupt HIV treatment to make room for HCV treatment. Stopping antiretroviral therapy in a coinfected person is linked to more cardiovascular events and faster liver scarring.[8] If drug interactions are a concern, the HIV regimen can be adjusted instead. With today's options, every coinfected person can be safely and successfully treated for both viruses.
Cost & AccessInsurance, Cost, and "You're Not Sober Enough"
DAA therapy has a list price in the tens of thousands of dollars — and almost nobody pays that. Medicaid, Medicare, Ryan White, most private insurance, and manufacturer patient assistance programs now cover DAA treatment for people living with HIV who also have HCV.[15] The barrier is rarely the drug itself; the barrier is prior authorization and outdated restrictions.
In the early DAA years, many state Medicaid programs would only cover treatment for people who had already progressed to advanced liver disease (F3 or F4), who could document six or twelve months of sobriety, or who were seen only by specialist hepatologists. After federal guidance and years of advocacy pressure, most of those restrictions have been rolled back — but not everywhere, and not always consistently.[15]
If you hear "you need to be sober first" — that guidance is out of date. The AASLD-IDSA HCV Guidance is explicit: substance use is not a reason to defer HCV treatment.[7] If you've been told otherwise, you have options. Ask your provider or insurer for a formal appeal in writing. Contact a hepatitis C patient advocacy line. In Florida, contact your local Ryan White program or a federally qualified health center — they can help navigate coverage denials.
What to ask when starting the process:
- Which DAA regimens are on my plan's formulary?
- Is prior authorization required, and what documentation does it need?
- Are there any fibrosis-stage, sobriety, or prescriber restrictions on my plan?
- If I'm uninsured or underinsured, does the manufacturer offer a patient assistance program? (Both Mavyret and Epclusa have them.)
Drug InteractionsART and DAAs — What to Watch For
Drug interactions between HIV medication and DAA hepatitis C medication are the main thing care teams have to think through in coinfection. The good news: most modern HIV regimens are compatible with first-line DAAs, and the interactions that do exist are well mapped out and manageable.
Key interactions to know: Efavirenz significantly lowers velpatasvir levels, so sofosbuvir/velpatasvir (Epclusa) should not be combined with an efavirenz-based HIV regimen. Etravirine and nevirapine also are not recommended with sofosbuvir/velpatasvir. Integrase inhibitors (dolutegravir, bictegravir, raltegravir) are generally safe with all first-line DAAs. Protease inhibitors may need closer attention.[7] Your HIV provider and hepatologist should be in touch with each other — not treating you in separate silos.
Because there are multiple effective regimens for both HIV and HCV, there is always a compatible combination. No one should be told they "can't be treated" for hepatitis C because of their HIV medications. If you hear that, ask for a second opinion.
After CureWhat Happens After HCV Is Cured?
If you did not have cirrhosis before treatment: Your liver can fully recover. Keep in touch with your provider, but the outlook is excellent.
If you had cirrhosis before cure: Curing hepatitis C stops the progression of liver disease and lowers — though does not eliminate — the risk of liver cancer. People with cirrhosis who reach SVR should continue liver cancer screening with an ultrasound every six months.[9] Some cirrhosis improves over time; some doesn't fully reverse.
Reinfection monitoring: Because cure doesn't create immunity, people with ongoing risk should have annual HCV RNA testing. This matters most for people who inject drugs and for gay and bisexual men with ongoing sexual risk.
Hepatitis B screening first. Anyone starting HCV treatment should be screened for hepatitis B (HBsAg, anti-HBs, anti-HBc). In rare cases, hepatitis B can reactivate when DAA treatment starts, so this needs to be identified up front.[10] People living with HIV who show evidence of HBV should be on an antiretroviral regimen that also covers HBV — usually one containing tenofovir.
If It Happens AgainReinfection Isn't a Moral Failure — And Retreatment Works
If you were cured of hepatitis C and later test positive again, that isn't a personal failure. It's a documented, well-studied outcome — especially for people who inject drugs and gay and bisexual men with ongoing sexual risk. Because cure doesn't create immunity, any new exposure can lead to a new infection.[16]
Retreatment works. In the DAA era, the same regimens (or slightly modified ones) cure people the second time around at similar rates to first-time treatment. Nobody should be denied retreatment because a provider disapproves of how the reinfection happened.[7]
What actually prevents reinfection. Cure isn't a shield — pair it with what does prevent HCV transmission: sterile injection equipment every time, syringe services programs, HIV PrEP for HIV-negative partners, and post-exposure medical care if a known exposure happens. If you inject drugs and your area doesn't have a syringe services program, harm-reduction organizations can ship sterile supplies to your door confidentially.
For People Who Inject DrugsHCV Treatment Is Yours Too
If you inject drugs and live with HIV, you are exactly the person modern DAAs were designed for. Clinical trials that specifically enrolled people actively injecting drugs — including SIMPLIFY and D3FEAT — showed cure rates equivalent to any other group.[17] You do not have to stop using to get treated. You do not need to be in a treatment program first. You do not need a specialist referral in most cases — a primary care provider, HIV provider, or Infectious Diseases specialist can prescribe.
Syringe services programs (SSPs) are the single most effective way to prevent HCV reinfection and HIV acquisition among people who inject drugs. CDC calls them cost-effective, safe, and highly effective in reducing HIV transmission, especially when paired with medications for opioid use disorder and antiretroviral therapy.[18]
Florida ContextHIV/HCV Coinfection in Florida
Florida carries one of the highest combined HIV and HCV burdens in the country. High rates of injection drug use, high HIV prevalence, and real barriers to care in rural counties mean coinfection is common — and, in many cases, underdiagnosed.[11]
Ryan White clinics across Florida can connect people living with HIV to HCV treatment. Many federally qualified health centers (FQHCs) also provide hepatitis C testing and treatment, often at no or low cost.[12] If you are living with HIV and have never been tested for HCV — or you were tested years ago and have ongoing risk — ask your provider about testing at your next visit. The test is a simple blood draw. The cure is 8 to 12 weeks of pills.
Hepatitis C is curable. If you are living with HIV and have hepatitis C, treatment exists that can clear the virus in 8 to 12 weeks. Cure rates are over 95%. Your HIV status does not stand in the way of a cure. Talk to your provider. Get tested. Get treated.
References & Sources
- Centers for Disease Control and Prevention. "Viral Hepatitis Among People with HIV." Coinfection prevalence estimates (~21% overall; 62–80% among people who inject drugs with HIV), testing recommendations for people living with HIV. cdc.gov — Viral Hepatitis Among People with HIV ↩
- American Association for the Study of Liver Diseases & Infectious Diseases Society of America. "HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C — Persons With HIV/HCV Coinfection." Faster fibrosis progression and increased end-stage liver disease and hepatocellular carcinoma risk in coinfection. hcvguidelines.org — HIV/HCV Coinfection ↩
- Bosh KA, Coyle JR, Muriithi NW, et al. "HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities." Epidemiology and Infection, 2018. National coinfection surveillance and non-AIDS mortality context. pmc.ncbi.nlm.nih.gov — Coinfection surveillance study ↩
- Sayiner ZA, Haque U, Malik MU, Gurakar A. "Extrahepatic Manifestations of Hepatitis C Virus." Peer-reviewed review of HCV-associated cryoglobulinemic vasculitis, membranoproliferative glomerulonephritis (MPGN), and porphyria cutanea tarda. pmc.ncbi.nlm.nih.gov — HCV extrahepatic manifestations ↩
- Centers for Disease Control and Prevention. "Sexually Transmitted Infections Treatment Guidelines, 2021 — Viral Hepatitis." Documents sexual transmission of HCV among MSM with HIV, including association with group sex and chemsex. cdc.gov — STI Treatment Guidelines: Viral Hepatitis ↩
- Centers for Disease Control and Prevention. "Testing Recommendations for Hepatitis C Virus Infection." One-time HCV testing of all adults 18+, testing during each pregnancy, and periodic testing for people with ongoing risk factors including HIV. cdc.gov — HCV testing recommendations ↩
- American Association for the Study of Liver Diseases & Infectious Diseases Society of America. "HCV Guidance: Persons With HIV/HCV Coinfection." Modern DAA regimens deliver SVR rates comparable to HCV monoinfection (>95%) in coinfected persons; ART/DAA drug-interaction management. hcvguidelines.org — DAA efficacy & interactions ↩
- U.S. Department of Health and Human Services, ClinicalInfo. "Considerations for Antiretroviral Use in Special Patient Populations — Hepatitis C Virus/HIV Coinfection." Efavirenz–velpatasvir interaction; guidance against interrupting ART for HCV treatment. clinicalinfo.hiv.gov — HCV/HIV Coinfection ↩
- American Association for the Study of Liver Diseases. "Practice Guidance on Hepatocellular Carcinoma." HCC surveillance every six months by ultrasound recommended for cirrhotic patients, including those who achieve SVR after DAA therapy. aasld.org — HCC surveillance guidance ↩
- U.S. Food and Drug Administration. "FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C." Reactivation of HBV during or after DAA treatment; HBV screening required before starting DAAs. fda.gov — HBV reactivation with DAAs ↩
- Florida Department of Health. "State of the HIV Epidemic in Florida, 2023." Coinfection statistics by sex and mode of exposure; Florida-specific coinfection burden. floridahealth.gov — State of HIV Epidemic 2023 ↩
- Health Resources and Services Administration. "Ryan White HIV/AIDS Program." Federal funding stream that supports HIV care and, through Part B ADAP programs including in Florida, provides access to HCV treatment for eligible people living with HIV. ryanwhite.hrsa.gov — Ryan White HIV/AIDS Program ↩
- American Association for the Study of Liver Diseases & Infectious Diseases Society of America. "HCV Guidance: Testing and Staging — Assessment of Fibrosis Stage." Non-invasive fibrosis staging methods (FibroScan/transient elastography, APRI, FIB-4) endorsed as first-line for HCV. hcvguidelines.org — Testing and Staging ↩
- Centers for Disease Control and Prevention. "Testing for Hepatitis C Virus Infection: Recommended Testing Sequence." HCV antibody screening followed by HCV RNA (NAT) confirmatory testing on the same specimen when the antibody is reactive. cdc.gov — HCV testing sequence ↩
- National Viral Hepatitis Roundtable & Center for Health Law and Policy Innovation. "Hepatitis C: The State of Medicaid Access." Multi-year national report card on Medicaid HCV treatment restrictions (fibrosis stage, sobriety, prescriber type) and the ongoing rollback of those restrictions. stateofhepc.org — State of Medicaid Access ↩
- Rossi C, Butt ZA, Wong S, et al. "Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort." Journal of Hepatology, 2018. Documented reinfection rates and outcomes in DAA-cured populations, especially among people who inject drugs and MSM with HIV. pmc.ncbi.nlm.nih.gov — HCV reinfection after DAA cure ↩
- Grebely J, Dalgard O, Conway B, et al. "Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial." The Lancet Gastroenterology & Hepatology, 2018. SVR rates equivalent to non-PWID populations in participants actively injecting drugs. pubmed.ncbi.nlm.nih.gov — SIMPLIFY trial ↩
- Broz D, Zibbell J, Foote C, et al. "Syringe Services Programs' Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them." American Journal of Preventive Medicine, published via CDC. Evidence base for SSPs in preventing HIV and HCV transmission among people who inject drugs. cdc.gov — SSPs and HIV/HCV prevention ↩
Hepatitis C Is Curable. Get Tested. Get Treated.
If you're living with HIV, HCV testing should be part of your routine care. If you test positive, effective treatment exists — and it works just as well for people with HIV.
Find Care in FloridaUnderstanding Your LabsWellness Hub